CorMatrix, a company out of Roswell, Georgia, has won FDA clearance for the Cor PATCH epicardial patch. The device is indicated for use at the locations of aneurysms, in adults who have suffered a heart attack that led to the ventricular walls becoming thinner, or anywhere else where structural support or repair of the heart would be helpful.
The patch is made using the new generation of the CorMatrix ECM extracellular matrix, which, unlike other competing devices derived from animal tissues, does not have any nuclear remnants, bits of cell wall, or lipids. It does still carry over factors that help tissues to grow into the material. Gluteraldehyde, a common ingredient in similar products that may be associated with inflammation, is not in the ingredients list of the Cor PATCH.
“We have a unique opportunity to enhance the repair and recovery of heart muscle after injury using the Cor™ PATCH technology. This could be a game changer for patients undergoing surgical procedures aimed to increase the blood supply to damaged areas of their heart. My translational research provides an important foundation of data to support the clinical use of this technology as an epicardial patch during coronary bypass surgery. We can now directly target damaged muscle in addition to bypassing blocked vessels,” said Dr. Paul W.M. Fedak, Professor of Cardiac Surgery, Cumming School of Medicine, University of Calgary, Libin Cardiovascular Institute of Alberta.
Here’s an animation from CorMatrix describing their new product:
Product page: Cor PATCH…
Flashbacks: CorMatrix CanGaroo ECM Envelope for Cardiac Implants Gets European Green Light; Update on CorMatrix: Company Receives US Patents for Extracellular Matrix Heart Valve; CanGaroo Envelope Now Cleared in U.S. to Protect Implantable Neurostimulators; Carotid Tissue Repair Device Gets 510(k) Nod from FDA; CorMatrix’s Cardiac Tissue Repair Gets CE Mark